Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.
| Website | https://www.immutrin.com/ |
| Employees | 13 (7 on RocketReach) |
| Industry | Biotechnology Research |
Looking for a particular Immutrin employee's phone or email?
Mihriban Tuna is the CEO of Immutrin.
7 people are employed at Immutrin.